CHMP positive opinion for opioid dependence treatment with Zubsolv® (buprenorphine and naloxone) in Europe
·First regulatory milestone for Mundipharma/Orexo partnership in Europe Cambridge, UK, and Uppsala, Sweden – September 15, 2017 – Mundipharma and Orexo AB (publ.) today announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Zubsolv (buprenorphine and naloxone sublingual tablet) for use in the treatment of opioid dependence. The European Commission will now review the CHMP opinion and a final decision is expected in Q4, 2017. The two companies have worked collaboratively in completing the